STOCK TITAN

[SCHEDULE 13D/A] Orthofix Medical Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Juniper-affiliated investors reported a collective 7.2% beneficial stake in Orthofix Medical Inc. The Schedule 13D/A shows Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy together hold 2,845,106 common shares, calculated against 39,494,265 outstanding shares as of the July 31, 2025 record date. Juniper Targeted Opportunity Fund purchased 457,680 shares for approximately $6,357,158 between May 9, 2025 and September 25, 2025, and Juniper Multi-Strategy purchased 18,926 shares for approximately $220,256 between May 8, 2025 and June 17, 2025, all in the open market. The filing states no other contracts or arrangements regarding the shares and disclaims broader third-party rights to dividends or proceeds.

Investitori affiliati a Juniper hanno riportato una partecipazione complessiva beneficiaria del 7,2% in Orthofix Medical Inc. Il Schedule 13D/A mostra che Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities e Juniper Multi-Strategy, insieme, detengono 2.845.106 azioni ordinarie, calcolate su 39.494.265 azioni in circolazione al 31 luglio 2025, data di registro. Il Juniper Targeted Opportunity Fund ha acquistato 457.680 azioni per circa 6.357.158 dollari tra l’9 maggio 2025 e il 25 settembre 2025, e Juniper Multi-Strategy ha acquistato 18.926 azioni per circa 220.256 dollari tra l’8 maggio 2025 e il 17 giugno 2025, tutti sul mercato aperto. La dichiarazione indica che non esistono altri contratti o accordi riguardo alle azioni e rinuncia a diritti di terzi più ampi su dividendi o proventi.

Inversores vinculados a Juniper reportaron una participación beneficiosa colectiva del 7,2% en Orthofix Medical Inc. El Schedule 13D/A muestra que Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities y Juniper Multi-Strategy, en conjunto, poseen 2.845.106 acciones comunes, calculadas sobre 39.494.265 acciones en circulación a la fecha de registro del 31 de julio de 2025. El Juniper Targeted Opportunity Fund compró 457.680 acciones por aproximadamente 6.357.158 dólares entre el 9 de mayo de 2025 y el 25 de septiembre de 2025, y Juniper Multi-Strategy compró 18.926 acciones por aproximadamente 220.256 dólares entre el 8 de mayo de 2025 y el 17 de junio de 2025, todo en el mercado abierto. La presentación indica que no existen otros contratos o acuerdos sobre las acciones y renuncia a derechos de terceros más amplios sobre dividendos o ingresos.

Juniper 소속 투자자들이 Orthofix Medical Inc.에 대해 총 7.2%의 유익한 지분을 보고했습니다. Schedule 13D/A에 따르면 Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities, Juniper Multi-Strategy가 합쳐 2,845,106주를 보유하고 있으며, 이는 2025년 7월 31일의 등기 기준 발행주식 39,494,265주에 대한 계산치입니다. Juniper Targeted Opportunity Fund는 2025년 5월 9일에서 2025년 9월 25일 사이에 약 6,357,158달러에 457,680주를, Juniper Multi-Strategy는 2025년 5월 8일에서 2025년 6월 17일 사이에 약 220,256달러에 18,926주를 각각 공개시장 매수했습니다. 보고서는 주식과 관련된 다른 계약이나 합의가 없으며 배당금이나 수익에 대한 더 넓은 제3자 권리를 포기한다고 명시합니다.

Des investisseurs affiliés à Juniper ont signalé une participation bénéficiaire collective de 7,2% dans Orthofix Medical Inc. Le Schedule 13D/A montre que Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities et Juniper Multi-Strategy détiennent ensemble 2 845 106 actions ordinaires, calculées sur 39 494 265 actions en circulation au 31 juillet 2025, date d’enregistrement. Le Juniper Targeted Opportunity Fund a acheté 457 680 actions pour environ 6 357 158 dollars entre le 9 mai 2025 et le 25 septembre 2025, et Juniper Multi-Strategy a acheté 18 926 actions pour environ 220 256 dollars entre le 8 mai 2025 et le 17 juin 2025, le tout sur le marché libre. Le dépôt indique qu’il n’existe pas d’autres contrats ou arrangements concernant les actions et renonce à des droits tiers plus larges sur les dividendes ou les produits.

Von Juniper zugehörige Investoren meldeten eine kollektive nützliche Beteiligung von 7,2% an Orthofix Medical Inc. Der Schedule 13D/A zeigt, dass Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities und Juniper Multi-Strategy zusammen 2.845.106 Stammaktien halten, berechnet gegenüber 39.494.265 ausstehende Aktien zum Stichtag 31. Juli 2025. Der Juniper Targeted Opportunity Fund kaufte 457.680 Aktien für ca. 6.357.158 USD zwischen dem 9. Mai 2025 und dem 25. September 2025, und Juniper Multi-Strategy kaufte 18.926 Aktien für ca. 220.256 USD zwischen dem 8. Mai 2025 und dem 17. Juni 2025, jeweils an der offenen Börse. Die Einreichung erklärt, dass es keine weiteren Verträge oder Vereinbarungen hinsichtlich der Aktien gibt und verzichtet auf breitere Rechte Dritter an Dividenden oder Erlösen.

أفاد المستثمرون المرتبطون بـ Juniper بحصة فائدة جماعية قدرها 7.2% في Orthofix Medical Inc. يبيّن Schedule 13D/A أن Juniper Targeted Opportunity Fund و Juniper Targeted Opportunities و Juniper Multi-Strategy معاً يمتلكون 2,845,106 أسهم عادية، محسوبة مقابل 39,494,265 سهم قائم اعتباراً من تاريخ السجل في 31 يوليو 2025. اشترى Juniper Targeted Opportunity Fund 457,680 سهماً مقابل نحو 6,357,158 دولاراً بين 9 مايو 2025 و25 سبتمبر 2025، واشتريت Juniper Multi-Strategy 18,926 سهماً مقابل نحو 220,256 دولاراً بين 8 مايو 2025 و17 يونيو 2025، وكل ذلك في السوق المفتوحة. تشير البلاغ إلى عدم وجود أي عقود أو ترتيبات أخرى تتعلق بالأسهم وتتنازل عن حقوق طرف ثالث أوسع فيما يتعلق بالأرباح أو العوائد.

与 Juniper 相关的投资者报告在 Orthofix Medical Inc. 的合计受益股权为7.2%。 Schedule 13D/A 显示,Juniper Targeted Opportunity Fund、Juniper Targeted Opportunities 和 Juniper Multi-Strategy 合计持有 2,845,106 股普通股,基于 2025 年 7 月 31 日的在外流通股本 39,494,265 股进行计算。Juniper Targeted Opportunity Fund 在 2025 年 5 月 9 日至 2025 年 9 月 25 日期间购买了 457,680 股,约合 6,357,158 美元;Juniper Multi-Strategy 在 2025 年 5 月 8 日至 2025 年 6 月 17 日之间购买了 18,926 股,约合 220,256 美元,均在公开市场交易。文件指出不存在关于这些股票的其他合同或安排,并且放弃对股息或收益的更广泛的第三方权利。

Positive
  • Material disclosed stake: Reporting Persons collectively hold 2,845,106 shares (7.2%) of Orthofix based on the July 31, 2025 record date.
  • Open-market purchases disclosed: Juniper Targeted Opportunity Fund acquired 457,680 shares for ~$6.36 million and Juniper Multi-Strategy acquired 18,926 shares for ~$220,256.
  • No special arrangements: The filing states there are no contracts, arrangements, or understandings regarding the securities beyond normal advisory/partner relationships.
Negative
  • None.

Insights

TL;DR: Juniper entities have built a meaningful 7.2% stake through open-market purchases, signaling concentrated investor interest.

The filing documents a collective 2,845,106 share position equal to ~7.2% of Orthofix based on the issuer's July 31, 2025 share count. Purchases were executed in the open market with disclosed aggregate consideration: ~$6.36 million for 457,680 shares by Juniper Targeted Opportunity Fund and ~$220k for 18,926 shares by Juniper Multi-Strategy. For investors, an activist or strategic intent is not explicitly stated; however, filing under Schedule 13D requires disclosure and often precedes engagement. The absence of contracts, arrangements, or special rights suggests the position is currently passive although material in size relative to outstanding float.

TL;DR: The filing discloses beneficial ownership and voting powers but shows no agreements or coordination beyond normal manager relationships.

Reporting persons include investment funds, their general partners, the investment advisor, and two managing members. The filing clarifies sole voting/dispositive power for each fund's holdings and disclaims broader beneficial ownership by affiliated entities and individuals for other purposes. Item 6 states there are no contracts or understandings concerning voting or transfer of the shares. From a governance perspective, this is transparent disclosure of ownership and control lines without current contractual governance commitments.

Investitori affiliati a Juniper hanno riportato una partecipazione complessiva beneficiaria del 7,2% in Orthofix Medical Inc. Il Schedule 13D/A mostra che Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities e Juniper Multi-Strategy, insieme, detengono 2.845.106 azioni ordinarie, calcolate su 39.494.265 azioni in circolazione al 31 luglio 2025, data di registro. Il Juniper Targeted Opportunity Fund ha acquistato 457.680 azioni per circa 6.357.158 dollari tra l’9 maggio 2025 e il 25 settembre 2025, e Juniper Multi-Strategy ha acquistato 18.926 azioni per circa 220.256 dollari tra l’8 maggio 2025 e il 17 giugno 2025, tutti sul mercato aperto. La dichiarazione indica che non esistono altri contratti o accordi riguardo alle azioni e rinuncia a diritti di terzi più ampi su dividendi o proventi.

Inversores vinculados a Juniper reportaron una participación beneficiosa colectiva del 7,2% en Orthofix Medical Inc. El Schedule 13D/A muestra que Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities y Juniper Multi-Strategy, en conjunto, poseen 2.845.106 acciones comunes, calculadas sobre 39.494.265 acciones en circulación a la fecha de registro del 31 de julio de 2025. El Juniper Targeted Opportunity Fund compró 457.680 acciones por aproximadamente 6.357.158 dólares entre el 9 de mayo de 2025 y el 25 de septiembre de 2025, y Juniper Multi-Strategy compró 18.926 acciones por aproximadamente 220.256 dólares entre el 8 de mayo de 2025 y el 17 de junio de 2025, todo en el mercado abierto. La presentación indica que no existen otros contratos o acuerdos sobre las acciones y renuncia a derechos de terceros más amplios sobre dividendos o ingresos.

Juniper 소속 투자자들이 Orthofix Medical Inc.에 대해 총 7.2%의 유익한 지분을 보고했습니다. Schedule 13D/A에 따르면 Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities, Juniper Multi-Strategy가 합쳐 2,845,106주를 보유하고 있으며, 이는 2025년 7월 31일의 등기 기준 발행주식 39,494,265주에 대한 계산치입니다. Juniper Targeted Opportunity Fund는 2025년 5월 9일에서 2025년 9월 25일 사이에 약 6,357,158달러에 457,680주를, Juniper Multi-Strategy는 2025년 5월 8일에서 2025년 6월 17일 사이에 약 220,256달러에 18,926주를 각각 공개시장 매수했습니다. 보고서는 주식과 관련된 다른 계약이나 합의가 없으며 배당금이나 수익에 대한 더 넓은 제3자 권리를 포기한다고 명시합니다.

Des investisseurs affiliés à Juniper ont signalé une participation bénéficiaire collective de 7,2% dans Orthofix Medical Inc. Le Schedule 13D/A montre que Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities et Juniper Multi-Strategy détiennent ensemble 2 845 106 actions ordinaires, calculées sur 39 494 265 actions en circulation au 31 juillet 2025, date d’enregistrement. Le Juniper Targeted Opportunity Fund a acheté 457 680 actions pour environ 6 357 158 dollars entre le 9 mai 2025 et le 25 septembre 2025, et Juniper Multi-Strategy a acheté 18 926 actions pour environ 220 256 dollars entre le 8 mai 2025 et le 17 juin 2025, le tout sur le marché libre. Le dépôt indique qu’il n’existe pas d’autres contrats ou arrangements concernant les actions et renonce à des droits tiers plus larges sur les dividendes ou les produits.

Von Juniper zugehörige Investoren meldeten eine kollektive nützliche Beteiligung von 7,2% an Orthofix Medical Inc. Der Schedule 13D/A zeigt, dass Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities und Juniper Multi-Strategy zusammen 2.845.106 Stammaktien halten, berechnet gegenüber 39.494.265 ausstehende Aktien zum Stichtag 31. Juli 2025. Der Juniper Targeted Opportunity Fund kaufte 457.680 Aktien für ca. 6.357.158 USD zwischen dem 9. Mai 2025 und dem 25. September 2025, und Juniper Multi-Strategy kaufte 18.926 Aktien für ca. 220.256 USD zwischen dem 8. Mai 2025 und dem 17. Juni 2025, jeweils an der offenen Börse. Die Einreichung erklärt, dass es keine weiteren Verträge oder Vereinbarungen hinsichtlich der Aktien gibt und verzichtet auf breitere Rechte Dritter an Dividenden oder Erlösen.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Juniper Targeted Opportunity Fund, L.P.
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member of its General Partner, Juniper HF Investors II, LLC
Date:09/25/2025
Juniper HF Investors II, LLC
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member
Date:09/25/2025
Juniper Targeted Opportunities, L.P.
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member of its General Partner, Juniper Targeted Opportunity Investors, LLC
Date:09/25/2025
Juniper Targeted Opportunity Investors, LLC
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member
Date:09/25/2025
Juniper Multi-Strategy Fund, L.P.
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member of its General Partner, Juniper Targeted Opportunity Investors, LLC
Date:09/25/2025
Juniper HF Investors, LLC
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member
Date:09/25/2025
Juniper Investment Company, LLC
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member
Date:09/25/2025
Alexis P. Michas
Signature:/s/ Alexis P. Michas
Name/Title:Managing Member
Date:09/25/2025
John A. Bartholdson
Signature:/s/ John A. Bartholdson
Name/Title:Managing Member
Date:09/25/2025

FAQ

What percentage of Orthofix (OFIX) do Juniper entities now own?

The Reporting Persons collectively beneficially own 2,845,106 shares, representing approximately 7.2% of Orthofix based on 39,494,265 outstanding shares as of July 31, 2025.

How were the shares acquired by Juniper funds?

The disclosed purchases were effected in the open market through a broker; Juniper Targeted Opportunity Fund and Juniper Multi-Strategy made the listed acquisitions.

What were the disclosed purchase amounts and dates?

Juniper Targeted Opportunity Fund purchased 457,680 shares for approximately $6,357,158 between May 9, 2025 and September 25, 2025; Juniper Multi-Strategy purchased 18,926 shares for approximately $220,256 between May 8, 2025 and June 17, 2025.

Do the reporting persons have any special agreements regarding voting or transfer of OFIX shares?

No. Item 6 states there are no contracts, arrangements, understandings or relationships with respect to the Issuer’s securities other than those described in the Schedule 13D/A.

Who are the individuals named in the filing?

The filing names Alexis P. Michas and John A. Bartholdson as managing members of the Juniper entities; both are U.S. citizens and signed the Schedule 13D/A.
Orthofix Med Inc

NASDAQ:OFIX

OFIX Rankings

OFIX Latest News

OFIX Latest SEC Filings

OFIX Stock Data

567.93M
38.53M
2.76%
91.93%
4.6%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LEWISVILLE